Role of calcitonin gene-related peptide in cerebral vasospasm, and as a therapeutic approach to subarachnoid hemorrhage

Citation for published version:
DOI: 10.3389/fendo.2012.00135

Digital Object Identifier (DOI):
10.3389/fendo.2012.00135

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Frontiers in Endocrinology

Publisher Rights Statement:
Copyright © Kokkoris, Andrews and Webb. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Role of calcitonin gene-related peptide in cerebral vasospasm, and as a therapeutic approach to subarachnoid hemorrhage

Stelios Kokkoris1, Peter Andrews2* and David J. Webb3

1 Intensive Care Unit, Western General Hospital, Edinburgh, UK
2 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
3 Clinical Pharmacology Unit, British Heart Foundation Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

*Correspondence: Peter Andrews, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. E-mail: p.andrews@ed.ac.uk

Calcitonin gene-related peptide (CGRP) is one of the most potent microvascular vasodilators identified to date. Vascular relaxation and vasodilation is mediated via activation of the CGRP receptor. This atypical receptor is made up of a G protein-coupled receptor called calcitonin receptor-like receptor (CCLP), a single transmembrane protein called receptor activity-modifying protein (RAMP), and an additional protein that is required for Ga coupling, known as receptor component protein (RCP). Several mechanisms involved in CGRP-mediated relaxation have been identified. These include nitric oxide (NO)-dependent endothelium-dependent mechanisms or cAMP-mediated endothelium-independent pathways; the latter being more common. Subarachnoid hemorrhage (SAH) is associated with cerebral vasoconstriction that occurs several days after the hemorrhage and is often fatal. The vasospasm occurs in 30–40% of patients and is the major cause of death from this condition. The vasoconstriction is associated with a decrease in CGRP levels in nerves and an increase in CGRP levels in draining blood, suggesting that CGRP is released from nerves to oppose the vasoconstriction. This evidence has led to the concept that exogenous CGRP may be beneficial in a condition that has proven hard to treat. The present article reviews: (a) the pathophysiology of delayed ischemic neurologic deficit after SAH (b) the basics of the CGRP receptor structure, signal transduction, and vasodilatation mechanisms and (c) the studies that have been conducted so far using CGRP in both animals and humans with SAH.

Keywords: GPCR, CGRP, subarachnoid hemorrhage, cerebral vasospasm, G proteins

INTRODUCTION

In the US, over 30,000 persons each year experience a subarachnoid hemorrhage (SAH). Whereas intracranial aneurysms are found in 2–5% of all autopsies, the incidence of rupture is only 2–28/100,000 individuals/year (Ingall et al., 2000). SAH is more frequent in women than men (3:2 ratio) over the age of 40, but the reverse is the case in those younger than 40 (The ACROSS Group, 2000; Ohkuma et al., 2002). Peak rupture rates occur between the ages of 50 and 60 years (The ACROSS Group, 2000; Ohkuma et al., 2002). Intracranial aneurysms account for approximately 85% of cases of non-traumatic SAH, whereas 10% have the pattern of non-aneurysmal perimesencephalic hemorrhage (van Gijn et al., 2007). In up to 15% of cases, no source of bleeding is identified (Kim et al., 2012). Approximately 10–15% of patients die before receiving medical treatment from the initial bleed or its immediate complications (Ingall et al., 2000). Those that survive the initial bleed are at risk for a number of secondary insults including rebleeding (Winic et al., 1977; Ohkuma et al., 2001), hydrocephalus, and cerebral vasospasm (van Gijn et al., 2007).

CGRP gene-related peptide (CGRP) is one of the most potent microvascular vasodilator peptides identified to date. In the cerebral circulation, CGRP is released from sensory fibers originating in the trigeminal ganglia and acts to dilate cerebral vessels (McCalliach et al., 1986). CGRP has been found to be at least 1,000 times more potent than acetylcholine, substance P, ATP, adenosine, and 5-hydroxytryptamine, and 10–100 times more potent than the β-adrenergic agonist isoprenaline. Consequently, a dose of 15 pmol injected into human skin produces an erythema that lasts for 5–6 h (Brain et al., 1985). As we discuss later, CGRP has a particularly potent vasodilator activity in the cerebral circulation, rendering it a promising agent for the treatment of SAH-triggered cerebral vasospasm.

In the present review, we summarize the etiology and therapy of cerebral vasospasm, the biology of CGRP and its receptors, and review the role of CGRP as a treatment in SAH-associated vasospasm in both animals and humans.
Angiographic vasospasm is a narrowing of the lumen of the major cerebral arteries, which is usually focal but may be diffuse. Vasospasm has its onset usually on day 3 after SAH, is maximal at days 6–8, and usually lasts for 2–3 weeks (Wilkins, 1990). Symptomatic vasospasm is characterized by the insidious onset of confusion and decreased level of consciousness, followed by focal motor and/or speech impairments. It is mainly a diagnosis of exclusion, when clinical deterioration occurs and hydrocephalus, rebleeding, hypoxia, and metabolic abnormalities have been ruled out. DCI is defined as symptomatic vasospasm, infarction attributable to vasospasm, or both (Frontera et al., 2009). Although about 70% of patients may develop arterial narrowing, only 30% will manifest neurological deficits. The outcome of DCI itself is death in about one-third and permanent deficit in another third (Dreisch, 1995). In the present review the term vasospasm is defined as arterial vessel narrowing.

**VASOSPASM PATHOPHYSIOLOGY**

**Nitric oxide**

Loss of the biological effect of nitric oxide (NO) is considered to play a pivotal permissive role in the development of cerebral vasospasm. The principal effect of NO on cerebral vessels is the relaxation of vascular smooth muscle cells, with decreased bioavailability of NO being implicated in the formation of SAH-induced vasospasm. The depletion of NO has been assumed to occur via several mechanisms in the setting of SAH. First, due to its high affinity for hemoglobin (Hb), NO is scavenged by Hb released during the breakdown of subarachnoid blood (Goretski and Hollocher, 1988; Ignarro, 1990). Second, it is possible that the production of NO is decreased in SAH, as a result of the down-regulation of endothelial NO synthase (eNOS) and neuronal NOS (nNOS; Pluta, 2005). This is supported by studies that revealed the down-regulation/dysfunction of eNOS, and loss of nNOS in spastic arteries after SAH (Hino et al., 1996; Pluta et al., 1996), as well as the finding that levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of eNOS, are elevated in the setting of cerebral vasospasm (Jung et al., 2004). Third, NO may reverse the effects of the potent vasocnstrictor endothelin-1 (ET-1; Thomas et al., 1997). Therefore, in the setting of decreased NO levels, the balance of vasodilator and vasoconstrictor influences is altered, and the relatively increased actions of ET-1 can potentiate cerebral vasospasm.

**Endothelin-1**

ET-1 is an extremely potent vasoconstrictor. In the brain, it is primarily produced by endothelial cells in response to ischemia, though it can also be produced by neurons, astrocytes, and activated leukocytes (Fassbender et al., 2000; Chow et al., 2002; Dumont et al., 2003). Levels of ET-1 are high in the plasma and cerebrospinal fluid (CSF) of SAH patients, correlate with the persistence of cerebral vasospasm (Seifert et al., 1995; Jouvel, 2000), and decline in the absence of vasospasm (Seifert et al., 1995). Conversely, the administration of ET-1 antagonists or endothelin converting enzyme inhibitors prevents vasospasm (Koutrou et al., 2002; Macdonald et al., 2008). Lastly, ET-1 induces NADPH oxidase expression and oxidative stress in human endothelial cells (Duerrschmidt et al., 2000).

**Inflammation**

Expression of adhesion molecules facilitates leukocyte adherence to the endothelium. Adhesion molecules, such as ICAM-1, VCAM-1, and E-selectin, have been found to be elevated in the CSF of patients with SAH and in blood vessels walls exposed to clot (Polin et al., 1998; Dumont et al., 2003). Leukocytes can contribute to vasospasm by promoting free radical formation that may evoke endothelial dysfunction (Grieham et al., 1998; Sullivan et al., 2000), and by producing a variety of vasoactive substances, including ET-1 and cytokines (Fassbender et al., 2000). Several cytokines have been found to be up-regulated in cerebral vasospasm, including TNF-alpha, IL-1, IL-6, and IL-8 (Hirashima et al., 1997; Fassbender et al., 2001; Takizawa et al., 2001).

**Oxidative stress**

Oxyhemoglobin (OxyHb) may catalyze generation of reactive oxygen species (ROS). Free radicals are considered to play a pivotal role in cerebral vasospasm through various mechanisms. First, they can initiate lipid peroxidation, whose products, lipid peroxides, are capable of producing vasospasm and damaging the structure of arteries (Lin et al., 2006). Second, it has been hypothesized that ROS can activate the protein kinase C (PKC) pathway directly and indirectly, through enhancement of the metabolism of membrane phospholipids resulting from peroxidative damage. This, in turn, can lead to vasospasm (Asano and Matsui, 1999). Other possible vasoactive compounds are bilirubin oxidation products (BOXes). Once bilirubin is formed, it is subsequently oxidized into BOXes, reaching maximum concentrations during the peak vasospasm period of 4–11 days. They are thought to be potentiators of cerebral vasospasm once it has been initiated, rather than primary initiators (Clark and Sharp, 2006).

**Hemoglobin**

A large body of evidence suggests that OxyHb, the ferrous form of hemoglobin, released from lysed erythrocytes, is a mediator of vasospasm. More specifically, OxyHb causes prolonged contraction of isolated cerebral arteries (Toda et al., 1991), and intracranial injections of this agent result in cerebral vasospasm (Macdonald et al., 1991). Indeed, the presence of OxyHb in the CSF of patients after SAH and the extent of hemorrhage are directly correlated with the distribution, severity, and time course of vasospasm (Mayberg et al., 1990). Ferrous hemoglobin released from subarachnoid clot could lead to delayed arterial narrowing by a number of mechanisms, such as scavenging or decreased production of NO (Pluta, 2005), free radical production, modification of K+ and Ca2+ channels (Ishiguro et al., 2008), differential up-regulation of genes (Vikman et al., 2006), and activation of the Rho/Rho kinase and PKC pathways (Wickman et al., 2003).

**Intracellular Ca2+**

Vasospasm can be regarded as an abnormal and prolonged contraction of vascular smooth muscle. The intracellular free Ca2+ levels increase in cerebral vessels exposed to clot (Polin et al., 1998; Dumont et al., 2003). Leukocytes can contribute to vasospasm by promoting free radical formation that may evoke endothelial dysfunction (Grieham et al., 1998; Sullivan et al., 2000), and by producing a variety of vasoactive substances, including ET-1 and cytokines (Fassbender et al., 2000). Several cytokines have been found to be up-regulated in cerebral vasospasm, including TNF-alpha, IL-1, IL-6, and IL-8 (Hirashima et al., 1997; Fassbender et al., 2001; Takizawa et al., 2001).
level plays a pivotal role in the regulation of smooth muscle contractility (Horszowitz et al., 1996). Following SAH, changes have been reported in the electrical properties of smooth muscle cells of small diameter cerebral arteries leading to enhanced Ca\(^{2+}\) influx, vasoconstriction, and decreased cerebral blood flow (Koide et al., 2011). Cerebral arteries from healthy animals express only L-type voltage-dependent Ca\(^{2+}\) channels. Expression of an additional type of voltage-dependent Ca\(^{2+}\) channels (R-type) occurs after SAH, leading to increased Ca\(^{2+}\) channel density, increased Ca\(^{2+}\) influx, and vasoconstriction (Ishiguro et al., 2005).

**Cortical spreading depolarization**

This is a pathogenetic process that has attracted much attention lately. The term "cortical spreading depolarization" describes the wave of near-complete neuronal depolarization and neuronal swelling in the brain that is ignited when passive cation influx across the cellular membranes exceeds ATP-dependent Na\(^{+}\) and Ca\(^{2+}\) pump activity. The cation influx is followed by water influx and shrinkage of the extracellular space by ~70% (Dreier et al., 2009). Although the ignition of cortical spreading depolarization occurs passively, driven by electrical and diffusion forces, energy consumption paradoxically increases since Na\(^{+}\) and Ca\(^{2+}\) pumps are immediately activated to correct the intracellular Na\(^{+}\) and Ca\(^{2+}\) surge. As a consequence, regional cerebral blood flow increases during the neuronal depolarization phase. The opposite of this physiological hemodynamic response to cortical spreading depolarization is termed "the inverse hemodynamic response," and occurs when there is local dysfunction of the microvasculature. With the inverse response, severe microvascular spasm instead of vasodilatation is coupled to the neuronal depolarization phase, and the term "cortical spreading ischemia" describes the cortical spreading depolarization-induced perfusion deficit (Dreier et al., 2009).

**Neurogenic factors**

The cerebral arteries have sympathetic, parasympathetic, and sensory innervation. It has been postulated that SAH causes a derangement of neuronal regulatory mechanisms, which in turn leads to vascular smooth muscle contraction. The vasoconstriction is associated with a decrease in CGRP levels in cerebral perivascular nerves (Edvinsson et al., 1991) and an increase in CGRP levels in blood draining from the external jugular vein (Brol et al., 1990), suggesting that CGRP is released antidromically from trigeminal sensory perivascular nerves to oppose the vasoconstriction. This evidence has led to the concept that administration of CGRP may be beneficial in SAH-associated vasospasm. The molecular characteristics of CGRP and its use as a treatment option in SAH are reviewed in Sections "Calcitonin Gene-related Peptide Biology" and "Calcitonin Gene-related Peptide and SAH," respectively, of the present article.

**TREATMENT OF VASOSPASM**

The management of vasospasm involves routine "prophylactic" measures as well as more aggressive interventions, reserved for situations where there are signs or symptoms of DCI.

**Hemodynamic therapy**

The use of triple-H therapy (hypervolemia, hypertension, and hemodilution) stems from numerous clinical observations noting improvement in patients' clinical symptoms following induced hypertension and volume expansion (Kosnik and Hunt, 1976; Kassell et al., 1982). The relative contribution of each component is debated. However, there are many uncertainties for the use of prophylactic hemodynamic therapy following SAH. Two studies randomly assigned normovolemic or hypervolemic therapy to patients and reported no difference in the incidence of DCI between groups (Tennihan et al., 2008; Egge et al., 2001).

**Nimodipine**

Nimodipine is safe, cost-effective, and reduces the risk of poor outcome and secondary ischemia (Neil-Dwyer et al., 1987; Welty, 1987; Kostron et al., 1988; Mee et al., 1988), but has very modest effects. It is used prophylactically in all patients with SAH. Its precise mechanism of action remains unclear. Despite being shown to reduce the incidence of DCI and cerebral infarction in clinical trials, it has negligible effects on angiographic vasospasm; nimodipine may be neuroprotective by blocking Ca\(^{2+}\) influx at a neuronal level (Al-Tamimi et al., 2010).

**Intracisternal thrombolysis**

A meta-analysis looking at a total of 652 patients who were treated with intracisternal thrombolysis concluded that thrombolytic therapy had a statistically significant beneficial effect. However, the authors acknowledged the lack of large, randomized prospective trials (Amin-Hanjani et al., 2004).

**Endovascular techniques**

Endovascular techniques frequently play a role in the aggressive treatment of vasospasm. They include transluminal angioplasty and intra-arterial infusion of vasodilators (papaverin, nicardipine, verapamil, etc.; Brisman et al., 2006). Transluminal balloon angioplasty is very effective at reversing angiographic spasm of large proximal vessels and produces a sustained reversal of arterial narrowing (Brisman et al., 2006; Jestaedt et al., 2008). The optimal timing of angioplasty in relation to medical therapy is uncertain. Major complications occur in ~5% of procedures and include vessel rupture, occlusion, dissection, hemorrhagic infarction, and hemorrhage from unsecured aneurysms (Zwienenberg-Lee et al., 2006).

**Statins**

Statins have been shown to possess cholesterol-lowering-independent pleiotropic effects in different clinical settings, including a decrease in the incidence and duration of severe vasospasm as well as a reduction in the mortality rate after SAH (Lynch et al., 2005; Tseng et al., 2005, 2007). Statins are thought to be beneficial in the prevention of cerebral vasospasm by down-regulating inflammation and up-regulating the expression of eNOS and therefore NO (Sugawara et al., 2011). However, CONSCIOUS 1
study (a phase 2 trial) did not show a reduction in patient mortality, though the study was underpowered for this endpoint (the primary end point of this study was moderate or severe vasospasm within 14 days; Macdonald et al., 2008). CONSCIOUS 2 study (a phase 3 trial) included 1157 patients and its primary composite endpoint comprised all-cause mortality and vasospasm related morbidity. This study showed that diosmin at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome (Macdonald et al., 2011).

Erythropoietin (EPO) has also been examined in the setting of cerebral vasospasm. Apart from being potentially neuroprotective, EPO may play a role in preventing vasospasm by increasing the phosphorylation of eNOS (Banthamnam et al., 2005), a potentially important mechanism for increasing NO production. A recent randomized controlled trial (MASH 2) including 1204 patients did not show any benefit from intravenous (i.v.) magnesium sulfate administration in clinical outcome after aneurysmal SAH (Dohout Mees et al., 2012).

Other drugs under investigation are tizanidine, a free radical scavenger (Thaly et al., 1997), fusidial, a Rho-kinase inhibitor that inhibits vascular smooth muscle contraction (Shibuya et al., 1992), sodium nitrite, an NO donor (Pluta et al., 2005) and cisternal placement of prolonged-release nicardipine-loaded polymers (Kasuya et al., 2005).

**CALCITONIN GENE-RELATED PEPTIDE BIOLOGY**

Calcitonin gene-related peptide is widely distributed in the central and peripheral nervous systems, primarily in sensory fibers that are closely associated with blood vessels (Uddman et al., 1986). CGRP is often co-localized with other peptides in these fibers, especially the tachykinin substance P (Uddman et al., 1986). In the cerebral circulation, CGRP is released from sensory fibers originating in the trigeminal ganglia and acts to dilate cerebral vessels (McCulloch et al., 1986). In the gut, CGRP is also released from spinal afferents, where it dilates mucosal blood vessels and may protect against the acidic environment (Holzer, 2000).

CGRP-containing fibers also innervate coronary arteries of the heart (Gulbenkian et al., 1993).

The regulation of CGRP production is poorly understood. At a cellular level, nerve growth factor (NGF) up-regulates CGRP via the Ras/Raf/mitogen-activated protein kinase-1 (MEK-1)/p42/p44 pathway (Freeland et al., 2000). In the human circulation, CGRP has a half-life of approximately 7–10 min (Kraenzlin et al., 1985; Struthers et al., 1986). Regarding its metabolism, it seems that there is not an obvious mechanism, and it is probably broken down via a number of routes. First, mast cell tryptase has a potent effect in cleaving CGRP into inactive fragments, both in vivo and in vitro. More specifically, if both CGRP and substance P are released simultaneously, then CGRP could be inactivated by enzymes (tryptases), released by mast cells in response to substance P. This mechanism has been demonstrated in skin (Brain and Williams, 1988, 1989). Second, a matrix metalloproteinase II has the ability to metabolize CGRP and remove its vasodilator activity (Fernandez-Patron et al., 2000). Third, Sams-Nielsen et al. (2001) have provided evidence that CGRP is taken back up into sensory nerve terminals after repolarization in vitro. Finally, in the CSF, αCGRP is degraded by an endopeptidase that cleaves the peptide at the Lys16-Arg17 bond (Le Greves et al., 1989).
STRUCTURE OF CGRP RECEPTORS

Many peptides, including the CGRP family, mediate their actions via G protein-coupled receptors (GPCR). The GPCRs form the largest family of cell-surface proteins that are capable of interacting with an extracellular stimulus and transducing that stimulus to produce a reaction inside a cell (Pierce et al., 2002). All GPCRs have seven transmembrane spanning domains, an extracellular N-terminus and an intracellular C-terminus and can be divided into three families based on signature amino acid sequences. Family A is the largest and generally binds small molecules and short peptides. Receptors in this class have been studied extensively, including photoreceptor rhodopsin, as well as adrenergic...
and olfactory receptors. Family B receptors bind larger peptides in the range of 27 to approximately 50 amino acids (secretin, glucagons, VIP, etc.). These receptors mediate the actions of CGRP and related peptides (Poyner et al., 2002; Hoare, 2005). Family C receptors include glutamate and GABA B receptors (Pierce et al., 2002).

Calcitonin receptor-like receptor (CLR), which belongs to family B of the GPCRs, comprises the main functional unit of the CGRP receptor (Figure 2). It was not until McLatchie’s work (McLatchie et al., 1998) was published that it was recognized that a novel family of single transmembrane domain proteins, called receptor activity-modifying proteins (RAMP), were required to allow CLR to bind peptide and transduce signal. Three RAMPs have been identified so far (RAMP 1, RAMP 2, and RAMP 3). Each RAMP has a single transmembrane-spanning domain, a short intracellular C-terminal tail (∼9 amino acids) and a long extracellular-terminus (∼100 amino acids; McLatchie et al., 1998).

As a result of CLR and calcitonin receptor (CTR) interactions with RAMP, the International Union of Pharmacology (IUPHAR) nomenclature recognizes that CGRP interacts with CLR/RAMP 1 (CGRP 1) receptors, whereas AM interacts with CLR/RAMP 2 (AM 1) or CLR/RAMP 3 (AM 2) receptors. The CTR without RAMP is sufficient for calcitonin binding, but CTR with RAMP 1, 2, or 3 are AM 1, AM 2, and AM 3 receptors, respectively (Poyner et al., 2002).

The primary function of CLR is thought to be related to ligand binding, whereas the RAMP molecule plays a crucial role in receptor trafficking to the membrane and determination of receptor pharmacology. The RAMP family regulate the glycosylation and transport of the CTR. However, they are not CGRP receptors by themselves (McLatchie et al., 1998; Sexton et al., 2009). Terminal glycosylation of the receptor and transit from the endoplasmic reticulum/Golgi apparatus to the cell surface require interaction of CLR with RAMP (Sexton et al., 2009).

Calcitonin gene-related peptide receptor activation is known to involve several crucial elements, in common with other GPCRs, such as the presence of a proline “kink” in transmembrane helix TM6 (Conn et al., 2005), and a putative DRY motif equivalent (Conn et al., 2007), similar to family A GPCRs. There is also evidence suggesting stabilization of the CLR interaction with G "alpha s (Gα s) by another 17kDa intracellular membrane protein, called RCP (Evans et al., 2000).

The existence of two receptors, CGRP 1 and CGRP 2, was originally proposed in the late 1980s, with the CGRP 1 receptor being the predominant mediator of cardiovascular effects. This receptor classification was developed as a consequence of pharmacological studies carried out with different agonists and antagonists in a range of tissue preparations, especially the positive inotropic effect in the guinea pig or rat atrium for determination of CGRP 1 receptor activity, and the inhibition of electrically evoked twitch responses in the rat vas deferens for determination of CGRP 2 receptor activity (Dennis et al., 1989, 1990; Dumont et al., 1997). In general, receptors that can be antagonized by the 30-amino acid fragment of CGRP, CGRP 8−37, with an approximate pA 2 value of 7.0 are designated as CGRP 1 receptors, while those that CGRP 8−37 blocks with a pA 2 of 6.0 or less are classified as CGRP 2 receptors (Quirion et al., 1992; Poyner, 1995). However, it is questionable whether the CGRP 2 receptor is a single receptor type or whether it is, in fact, explained by multiple molecular entities (Hay, 2007).

![Figure 2](image_url)
In contrast, CGRP1 is a well-defined receptor type consisting of CLR and RAMP1.

**SIGNAL TRANSDUCTION OF CGRP RECEPTOR**

Several mechanisms involved in CGRP-mediated vasorelaxation have been identified. These mechanisms include either NO-dependent endothelium-dependent mechanisms or cAMP-mediated endothelium-independent pathways. The most common pathway is NO- and endothelium-independent. Activation of the CGRP receptor is generally accepted to result in Ga<sub>i</sub> or Ga<sub>o</sub>-mediated activation of adenylate cyclase, with a subsequent increase in cAMP and activation of protein kinase A (PKA). In the absence of endothelium, CGRP is able to cause relaxation, suggesting it must directly act on the smooth muscle cells to stimulate adenylate cyclase (Edvinsson et al., 1985, 1998; Crossman et al., 1990). The resulting rise in cAMP then activates PKA, which phosphorylates and opens up ATP-sensitive K<sup>+</sup> channels, thus leading to relaxation (Figure 3A; Nelson et al., 1990).

Endothelium-independent relaxation to CGRP occurs in the majority of tissues examined to date. Exceptions include the rat aorta, where the relaxation to CGRP occurs only in the presence of an intact endothelium and is attenuated by inhibitors of NO synthase, implying a NO-dependent mechanism (Brain et al., 1985; Gray and Marshall, 1992a,b). A significant increase in both cAMP and cGMP occurs and is also dependent on the presence of endothelium (Gray and Marshall, 1992a). This implicates the release of NO from the endothelium, which then relaxes the smooth muscle cells through activation of guanylate cyclase and accumulation of cGMP. Moreover, it has been shown that cAMP is able to stimulate eNOS activity, leading to increased synthesis and release of NO (Ferro et al., 1999; Queen et al., 2000). The activation of eNOS via cAMP is probably mediated via PKA, as a study demonstrated that various protein kinases can phosphorylate and activate eNOS (Burr et al., 2000). It is a possibility that CGRP causes an increase in cAMP in endothelial cells, which leads to PKA activation. PKA, in turn, activates eNOS, which results in NO release, and thus relaxation of the smooth muscle (Figure 3A).

There is some evidence for Ga<sub>i</sub> signaling by the CGRP receptor, which is traditionally identified by sensitivity to pertussis toxin (PTX; Figure 3B). The CGRP-mediated stimulation of Ca<sup>2+</sup> transients in rat nodose neurons and the activation of c-Jun N-terminal kinase (JNK) in SK-N-MC cells (which express endogenous CGRP receptors) both displayed PTX sensitivity (Willey et al., 1992; Disa et al., 2000).

![Figure 3](image-url)
The CGRP receptor may also be able to stimulate intracellular activity through different G protein. An animal study of experimental SAH in rats revealed that the sensitivity of the CGRP receptor involves Gα11, rather than through Gαq, suggesting that the activated CGRP receptor is able to interact with both types of G protein. If this mechanism is present in endothelial cells, it provides an alternative explanation for CGRP activation of eNOS (which is traditionally considered to be dependent on Ca2+/calmodulin for activation), independently of cAMP accumulation. The possibility that CGRP receptors may be coupled to phosphatidylinositol trisphosphate (IP3) activity. This increase in Ca2+ is proposed to be the most likely candidate.

Kokkoris et al. (1999) reported that CGRP was able to activate phospholipase C (PLC) in HEK293 cells, leading to an increase in intracellular Ca2+ activity that CGRP receptors may be coupled to phosphatidylinositol diacylglycerol (DG) turnover is supported by another study that found this secondary messenger pathway in skeletal muscle (Laufer and Changxue, 1989; Figure 3C).

Recently, Meens et al. (2011) reported that activated CGRP receptors induce cyclic nucleotide-independent relaxation of vascular smooth muscle cells in mesenteric resistance arteries and terminate arterial effects of ET-1 via Gαq. More specifically, CGRP receptor activation causes cAMP production but the relaxation of rat mesenteric resistance arteries induced by activation of this receptor involves Gαq, and is not dependent on cAMP (Figure 3D).

Another study by Meens et al. (2011) discovered that CGRP released from periartrial sensory motor nerves terminates long-lasting vasococontractor effects of ET-1 by promoting dissociation of ET-1/ETA-receptor complexes.

The CGRP receptor can also potentially activate other downstream signaling molecules, such as PKC and mitogen-activated protein kinase (MAPK) cascades, such as p38, JNK, and extracellular signal-regulated kinase (ERK). CGRP receptor signaling is regulated by desensitization, internalization, and trafficking, which, as with other GPCRs, involves GPCR kinases (GRK), β-arrestin, and clathrin- and dynamin-dependent endocytosis (Walker et al., 2010). Paillas et al. (2007) proposed a mechanism by which endosomal endothelin-1 converting enzyme-1 (ECE-1) degrades CGRP in endosomes to disrupt the peptide/receptor/β-arrestin complex, freeing internalized receptors from β-arrestins and promoting recycling and resensitization, resulting in long-lasting vascular relaxing response to CGRP.

CALCITONIN GENE-RELATED PEPTIDE AND SAH
PRELIMINARY OBSERVATIONAL STUDIES

A study of experimental SAH in rats revealed that the sensitivity of the cerebral circulation by CGRP-containing fibers appeared to be reduced after SAH (estimated by the number of fibers present), and was also located in the vasodilating response to CGRP in basilar arteries after SAH as compared to vessels from control animals. The reduction in CGRP could be due to release of the transmitter from the perivascular nerve terminals caused by blood in the subarachnoid space (Edvinsson et al., 1990).

In another study (Edvinsson et al., 1991), the proximal parts of the middle cerebral artery (MCA) were collected within 24 h after death from five humans suffering SAH (5–10 days beforehand) and from six subjects dying from myocardial infarction. In humans who had died from SAH the level of CGRP was nearly not detectable, being in contrast to that seen in age and sex matched subjects who had died of myocardial infarction. The trigemino-cerebrovascular system was suggested by the authors to act as an anti-vasoconstrictor system by releasing stored peptides, CGRP being the most likely candidate.

Joual et al. (1995) measured CGRP levels with specific radioimmunoassays (RIA) in patients with SAH, after operation with aneurysm clipping and nimodipine treatment. They used samples taken either from the external jugular vein (n = 20) or from the CSF (n = 14) during the postoperative course. They also used samples from healthy volunteers. The degree of vasoconstriction in the patients was monitored with Doppler ultrasound recordings. CGRP concentrations from the external jugular vein were significantly higher than from controls. Also, the CGRP level was measurable in SAH CSF but not in CSF of controls.

Others (Tran Dinh et al., 1994) showed that the basal level of endogenous CGRP in CSF was 0.77 nmol/L in rabbits. The CGRP concentration peaked at 14 nmol/L within 30 min, and at 8 nmol/L within 24 h, after SAH. They further showed that 3 days after SAH the CGRP concentration in CSF declined to 3.5 nmol/L.

Nozaki et al. (1989a) produced a model of SAH by a single injection of fresh autologous arterial blood into the cisterna magna of dogs. Then, they examined changes of CGRP immunoreactivity immunohistochemically in perivascular nerve fibers of the large pial arteries. CGRP in cerebrovascular nerve fibers was suppressed after SAH. The suppression was first detected on the third day after SAH, and was most marked during the 7th to 14th day. CGRP; however, recovered to a normal level by the 42nd day after SAH.

Arienta et al. (1991) isolated the basilar artery from five rabbits subjected to SAH and five control animals. A mild or severe Vasospasm was observed in the basilar artery about 15 min after injection of blood in the cisterna magna, while fluorescence immunohistochemistry revealed a marked decrease of the perivascular nerves containing CGRP in the animals of the experimental group, as compared to the control group.

EFFECTS OF CGRP ADMINISTRATION ON CEREBRAL VASOSPASM AFTER EXPERIMENTAL SAH IN ANIMALS (Table 1)

Nozaki et al. (1989b) produced experimental SAH in 30 dogs by injecting autologous arterial blood into the cisterna magna. They used two models of injection: in the first, single-injection model, 1 ml/kg of blood was injected on day 0, while 0.5 ml/kg of blood was injected successively 48 h apart in the second, double-injection model, on day 0 and day 2. The diameter of the basilar artery was measured by angiography. The most marked constriction of the basilar artery was seen on day 3 after SAH in the single-injection model and on day 7 in the double-injection model. When 10−7 mol/kg of CGRP was administered intracisternally (i.c.) on day 3 in the single-injection model, cerebral vasospasm reversed completely. The effect began to appear 5 min after CGRP administration, continued for 4 h, and disappeared by 24 h after the administration. When CGRP was administered at doses of 10−10 to 2 × 10−11 mol/kg on day 7 after SAH in the double-injection model, the cerebral vasospasm was reversed in a dose-dependent manner: 2 × 10−11 mol/kg of CGRP reversed the vasospasm completely. The effect began to appear 5 min after the CGRP...
administration, continued for 4 h, and disappeared by 24 h. Of note, when the amounts of CGRP mentioned above were administrated i.c., both mean arterial blood pressure and heart rate were only slightly increased and returned to the previous levels within several minutes.

In a similar study by Imai et al. (1996), experimental SAH was produced by i.c. injection of arterial blood in rabbits. The animals were treated with intrathecal administration of CGRP 3 days after SAH. The degree of vasospasm and the effect of CGRP were evaluated angiographically by measuring the basilar artery diameter. The basilar artery constricted to 73% of the pre-SAH values 3 days after SAH. Fifteen minutes after injection, the basilar artery dilated from 73 to 117% (p < 0.01). Similarly, the diameter of basilar artery in group 5 (i.v. CGRP) was significantly greater than that in group 4 (i.v. vehicle, p < 0.01). Although no significant difference was observed in mean arterial blood pressure between groups 2 and 3 (i.c. groups), there was a significant difference between i.v. groups 4 and 5 (lower in group 5, p < 0.01).

Ahmad et al. (1996) implanted a CGRP slow-release tablet i.c., containing either 24 or 153 μg of human CGRP, 24 h after experimental SAH was induced in rabbits. Following implantation, the CGRP level in the CSF remained elevated for 5 days. The implantation of the tablet almost completely ameliorated angiographic vasospasm. Moreover, no significant systemic hypotension or neurological adverse event was associated with the treatment.

In a similar approach, Inoue et al. (1996) investigated the efficacy of a CGRP slow-release tablet for the prevention of cerebral vasospasm after SAH in monkeys. Experimental SAH was produced by the method of Espinosa et al. (1984). The animal underwent a right frontotemporal craniectomy under sterile conditions. The dura mater was opened, and the arachnoid membrane was microsurgically incised until the ipsilateral internal carotid

<table>
<thead>
<tr>
<th>Reference</th>
<th>Animal model</th>
<th>Total sample size</th>
<th>Way of CGRP administration</th>
<th>CGRP dose</th>
<th>Results</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nozaki et al. (1989b)</td>
<td>Dog</td>
<td>30 (22/8)</td>
<td>i.c.</td>
<td>2 × 10⁻¹⁰ mol/kg</td>
<td>Vasospasm was reversed completely</td>
<td>AP and HR slightly increased</td>
</tr>
<tr>
<td>Imazumi et al. (1996)</td>
<td>Rabbit</td>
<td>16 (6/8)</td>
<td>i.c.</td>
<td>10⁻¹⁰ mol/kg</td>
<td>Basilar artery dilated from 73 to 117%, significantly larger than 67% in control (p &lt; 0.01)</td>
<td>None</td>
</tr>
<tr>
<td>Toshiba et al. (1992)</td>
<td>Rabbit</td>
<td>41 (17/24)</td>
<td>i.c., i.v.</td>
<td>100 ng/kg/min i.c., 100 ng/kg/min i.v.</td>
<td>Vasospasm was reversed completely</td>
<td>None</td>
</tr>
<tr>
<td>Imaizumi et al. (1996)</td>
<td>Dog</td>
<td>20 (8/12)</td>
<td>i.c.</td>
<td>10⁻¹⁰ mol/kg</td>
<td>Vasospasm was reversed completely</td>
<td>None</td>
</tr>
<tr>
<td>Ahmad et al. (1996)</td>
<td>Monkey</td>
<td>10 (5/5)</td>
<td>i.c.</td>
<td>24 or 153 μg</td>
<td>Vasospasm was completely reversed</td>
<td>None</td>
</tr>
<tr>
<td>Inoue et al. (1996)</td>
<td>Rabbit</td>
<td>16 (6/8)</td>
<td>i.c.</td>
<td>1,200 μg</td>
<td>Cerebral vasospasm was significantly ameliorated</td>
<td>None</td>
</tr>
<tr>
<td>Toyoda et al. (2000)</td>
<td>Rabbit</td>
<td>16 (6/8)</td>
<td>i.c.</td>
<td>NA</td>
<td>Arterial diameter was similar before and after SAH in CGRP group</td>
<td>None</td>
</tr>
<tr>
<td>Satoh et al. (2002)</td>
<td>Dog</td>
<td>20 (9/12)</td>
<td>i.c.</td>
<td>NA</td>
<td>Vasospasm was significantly reduced compared with the control group</td>
<td>None</td>
</tr>
</tbody>
</table>

i.c., intracisternally; i.v., intravenously; AP, arterial pressure; HR, heart rate; SAH, subarachnoid hemorrhage; NA, non-applicable.
Table 2 | Studies of CGRP administration after aneurysmal SAH in humans.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sample size/patient type</th>
<th>Study design</th>
<th>Way of CGRP administration</th>
<th>Dose</th>
<th>Primary outcome</th>
<th>Results</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Juul et al. (1994)</td>
<td>5/ postoperative course after SAH</td>
<td>Not randomized, not controlled study</td>
<td>i.v. infusion</td>
<td>0.6 μg/min</td>
<td>H.I.</td>
<td>Significant reduction in H.I. during CGRP infusion compared to that before infusion</td>
<td>HR increase during CGRP infusion</td>
</tr>
<tr>
<td>Johnston et al. (1990)</td>
<td>15/ neurological deficit after surgical clipping of the aneurysm</td>
<td>Multicenter randomized placebo-controlled study</td>
<td>i.v. infusion</td>
<td>0.035 μg/min, doubled every 10 min, max 1.15 μg/min</td>
<td>Modified GCS</td>
<td>Of the nine patients who showed a treatment preference, eight favored CGRP (p &lt; 0.09)</td>
<td>None</td>
</tr>
<tr>
<td>European CGRP in SAH study (1992)</td>
<td>117/ ischemic neurological deficit after operation for the aneurysm</td>
<td>Multicenter randomized placebo-controlled study</td>
<td>i.v. infusion</td>
<td>0.6 μg/min</td>
<td>Glasgow outcome scale</td>
<td>Relative risk of a bad outcome in CGRP-treated compared with controls 0.88 (95% CI: 0.6–1.26)</td>
<td>2/3 of the patients included in the CGRP group had reduced AP and did not complete treatment</td>
</tr>
</tbody>
</table>

i.v., intravenous; AP, arterial pressure; HR, heart rate; SAH, subarachnoid hemorrhage; H.I., hemodynamic index; GCS, Glasgow coma scale.
artery (ICA) and proximal portions of the MCA and anterior cerebral artery (ACA) were exposed. An autologous blood clot (1 ml/kg) was then placed around the exposed arteries to produce experimental SAH. For animals in the CGRP (n = 5) and placebo (n = 5) groups, a total of three tablets (total drug 1200 μg) were ipsilaterally placed under the frontal and temporal lobes at the time of SAH production. In the control group, cerebral vasospasm developed on day 7 (56% as an average of the ICA, MCA, and ACA). In the CGRP group, vasospasm was significantly ameliorated compared with that observed in the control group treated with placebo (the basilar artery diameter was 78% of baseline, p < 0.05 compared with the control SAH group). High levels of CGRP in CSF were eventually included in the study. Infusion started at a rate sufficient to deliver 0.035 μg/min CGRP, and was doubled every 10 min until either a clinical response was obtained or a maximum dose of 1.15 μg/min was reached at 1 h. If the neurological deficit had not deteriorated and the patient had no side-effects by that time, the maximum infusion rate was continued for another 20 min. Regarding neurological changes according to the modified Glasgow Coma Scale, five patients did not improve on either treatment, one improved on both, eight improved on CGRP but not on placebo, and one improved on placebo but not on CGRP. Of the nine patients who showed a treatment preference, eight (88.9%) favored CGRP (p < 0.05). The mean duration of neurological improvement was 25 min, after which patients returned to their previous neurological status. There was a significant decrease in both systolic and diastolic blood pressures during the infusion of CGRP.

A larger, multicenter, randomized controlled trial (European CGRP in SAH study, 1992) investigated the effect of a postoperative infusion of CGRP on outcome at 3 months. Patients with aneurysmal SAH who underwent surgery entered the trial if an ischemic neurological deficit developed after the operation. A total of 117 patients entered the study (62 patients received CGRP and 55 standard management). The CGRP-treated patients received the drug by i.v. infusion at a rate of 0.6 μg/min. If systemic hypotension developed, the infusion rate was reduced to 0.45 μg/min, then to 0.3 μg/min, if the hypotension was still apparent. CGRP treatment was given for at least 4 h; patients who showed a satisfactory neurological response continued to receive treatment for up to 10 days (minimum of 4 days). The percentage of patients with a good outcome was slightly but not significantly higher in the CGRP than in the control group. The relative risk of a bad outcome in CGRP-treated compared with control patients was 0.88 (95% CI 0.60–1.28). Interestingly, only a third of patients randomized to receive CGRP completed treatment, so two-thirds included in the treatment group for the analyses had limited exposure to CGRP, mainly due to arterial hypotension.

CONCLUSION

The pathogenesis of vasospasm after SAH is complex, multifactorial, and incompletely understood. CGRP has shown promising results both in vitro and in vivo, mainly in animal models of experimental SAH. However, there is a lack of studies in humans. Systemic hypotension induced by the i.v. administration of the drug seems to be a serious problem. The encouraging results from the i.c. application of CGRP in animals could warrant large studies in humans with CGRP instillation into the subarachnoid space, in order to avoid hypotension and achieve even more efficient dilatation of the cerebral arteries.


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 23 July 2012; accepted: 24 October 2012; published online: 15 November 2012.


The article was submitted to Frontiers in Neuroendocrine Science, a specialty of Frontiers in Endocrinology. Copyright © 2012 Kokkoris, Andrews and Webb. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third party graphics etc.